Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W R Ballou

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The American Journal of Tropical Medicine and Hygiene|July 1, 1996
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United StatesD M Gordon, P E Duffy, D G Heppner, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|May 1, 1991
Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malariaJ A Sherwood, C N Oster, M Adoyo-Adoyo, et al.
Infection and Immunity|May 1, 1996
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malariaD E Lanar, J A Tine, C de Taisne, et al.
Infection and Immunity|October 24, 2007
Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primatesS Pichyangkul, U Kum-Arb, K Yongvanitchit, et al.
The Journal of Infectious Diseases|February 15, 2001
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester, D A McKinney, N Tornieporth, et al.
Acta Tropica|September 30, 1997
SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in ThailandS Migasena, D G Heppner, D E Kyle, et al.
The American Journal of Tropical Medicine and Hygiene|February 16, 2000
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The GambiaJ F Doherty, M Pinder, N Tornieporth, et al.
Vaccine|October 16, 1999
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoidW A Keitel, K E Kester, R L Atmar, et al.
Vaccine|June 1, 1997
Selection of an adjuvant for vaccination with the malaria antigen, MSA-2D Pye, K L Vandenberg, S L Dyer, et al.
AIDS Research and Human Retroviruses|February 5, 2000
Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccinesL A Falk, K L Goldenthal, J Esparza, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The American Journal of Tropical Medicine and Hygiene|July 1, 1996
Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United StatesD M Gordon, P E Duffy, D G Heppner, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene|May 1, 1991
Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malariaJ A Sherwood, C N Oster, M Adoyo-Adoyo, et al.
Infection and Immunity|May 1, 1996
Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malariaD E Lanar, J A Tine, C de Taisne, et al.
Infection and Immunity|October 24, 2007
Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primatesS Pichyangkul, U Kum-Arb, K Yongvanitchit, et al.
The Journal of Infectious Diseases|February 15, 2001
Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malariaK E Kester, D A McKinney, N Tornieporth, et al.
Acta Tropica|September 30, 1997
SPf66 malaria vaccine is safe and immunogenic in malaria naive adults in ThailandS Migasena, D G Heppner, D E Kyle, et al.
The American Journal of Tropical Medicine and Hygiene|February 16, 2000
A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The GambiaJ F Doherty, M Pinder, N Tornieporth, et al.
Vaccine|October 16, 1999
Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoidW A Keitel, K E Kester, R L Atmar, et al.
Vaccine|June 1, 1997
Selection of an adjuvant for vaccination with the malaria antigen, MSA-2D Pye, K L Vandenberg, S L Dyer, et al.
AIDS Research and Human Retroviruses|February 5, 2000
Recombinant bacillus Calmette-Guérin as a potential vector for preventive HIV type 1 vaccinesL A Falk, K L Goldenthal, J Esparza, et al.
Pageof 10